The most commonly used biomarkers for ICI response in adult cancers are tumor mutational burden (TMB), expressed neoantigens, PD‐L1 and PD1 protein expression, various gene signatures, microsatellite instability, and specific somatic genetic alterations.21 This evidence concerns the gene CD274 and neoplasm.